Medication adherence is crucial to effective chronic disease management, yet little is known about the influence of the patient-provider interaction on medication adherence to hypertensive regimens. We aimed to examine the association between the patient's experience with care and medication adherence.
Original article
Hypertension affects about 30% of American adults and is one of the largest contributors to morbidity and mortality in the United States. [1] [2] [3] Although effective treatments are available, only about half of the patients with hypertension are effectively managed. 3 Improved control of hypertension offers the potential to lower the incidence of vascular disease and prevent a substantial numbers of deaths annually. [4] [5] [6] Medication nonadherence is one of the well-known contributors to suboptimal hypertension control. 7 Although patient behavior influences medication adherence, multiple system-level factors also affect medication adherence. [7] [8] [9] [10] [11] The majority of patients report some degree of medication nonadherence. 7, 12 Although physicians acknowledge the importance of medication adherence, nonadherence is not commonly recognized or addressed. 13, 14 There have been several interventions found to influence patient adherence to medication recommendations, including automated telephone calls, texts, and reminder packaging. [15] [16] [17] [18] However, a Cochrane review found that the available methods to improve adherence were inconsistent. 19 For instance, a cluster randomized trial of provider education, provider alerts, and patient education failed to show benefit in medication adherence. 20 Similarly, a large study of low-cost reminder devices failed to lead to improvements in medication adherence. 21 It is possible that reminder devices and other interventions need to be augmented with direct provider involvement for maximal benefit. A few studies have examined the influence of providers on patient medication adherence. [22] [23] [24] [25] For example, in a study of low-income hypertensive African American patients, communication that was rated as more collaborative was associated with better adherence to antihypertensive medications. 23 Similarly, medication adherence in older adults was significantly associated with provider communication. 24 Beyond provider communication, there remains a relatively limited understanding of how patientprovider interactions and the overall patient experience with care influences medication adherence.
To better delineate the role that the patient experience with care has in medication adherence, we aimed to (i) explore adherence to hypertension medications in a large underserved hypertensive population; (ii) examine the association between the patient experience with care and medication adherence; and (iii) examine the association between medication adherence and blood pressure (BP) control.
METHODS
We collected 2,128 surveys from 3 safety-net practices in Upstate New York to monitor medication adherence from July 2011 to March 2014. A total of 3,240 surveys were printed, but some that were printed were not ultimately handed out, yielding a minimum response rate of 65.7%. All 3 sites were located in federally designated underserved urban regions. The 3 practices varied from a federally qualified health center, an academic teaching institution, and a practice with a large refugee population. All practices included a racially diverse, economically disadvantaged population.
Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) questionnaire. 26, 27 We obtained written permission and followed the official scoring, imputation procedures, and exclusion criteria established by Dr Morisky. The survey began with an initial screening question to ensure that patients referred to high BP medications for their responses. It read:
Our records show that you have previously received care for high blood pressure (also called any type of hypertension). In addition, you have received a prescription for medicine to help control your blood pressure. If this is correct, please start with question #1 below.
The 8 MMAS-8 items followed this initial screening question, as provided under a license agreement. We scored the 8 items according to the provided instructions. Based on established standards, we reversed the coded response in a positive direction for the item "Did you take your high blood pressure medicine yesterday" and standardized the code for "How often do you have difficulty remembering to take all your medications?" The total MMAS scale has a range of 0 to 8.0, from low adherence to high adherence. A score of less than 6 corresponded to low adherence, a score equal to 6 but less than 8 corresponded to medium adherence, while a score equal to 8 was high adherence. To test the internal consistency, we ran a Cronbach's alpha reliability test. 26, 27 The Cronbach's alpha reliability coefficient for the MMAS in this study was 0.7. We followed the standard direction of using a 75% completion criterion of the 8 items for establishing eligibility and calculating the median value of all missing items as a substitute for the missing item for individuals meeting the eligibility criterion. Missing data were present on less than 5% of surveys. (See Supplementary Appendix Table S1 [available online] for complete medication adherence questions).
We used 8 measures of patient experience with care: (i) explanation the provider gave about the problem or condition, (ii) concern the provider showed for patient's question or worries, (iii) provider's efforts to include the patient in decisions about their treatment, (iv) information the provider gave about medications, (v) amount of time provider spent, (vi) overall rating of care received, (vii) recommendation of the provider, and (viii) recommendation of the clinic. All 8 patient experience measures were obtained from standard Press Ganey items and used a 5-point very-good to very-poor scale. The questionnaire was available in Spanish and English and a staff member was available to assist patients with low literacy. See Supplementary Appendix Table S1 [available online] for complete patient experience questions.
Self-identified race/ethnicity was recorded in 5 groups (White, African American, Hispanic, Asian, Other). General health status was measured with a single question: "In general, how would you rate your overall health?" using a 5-point Poor/Fair/Good/Very Good/Excellent scale, which is the self-reported overall general health item that is standard on Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys and used in standard case-mix adjustment for reporting of CAHPS patient experience scores. Because sicker patients tend to report worse experiences, we adjusted for health status.
We abstracted BP and comorbidity data from the electronic health record. The last BP recorded by the patient's primary care physician was used in the analysis. The control rate was calculated based on JNC-7 standards (accepted standards during the study period) and analyzed as a dichotomous variable (controlled or not controlled). We considered a patient without diabetes or chronic kidney disease to be controlled if they had a BP less than 140/90 mm Hg and considered patients with these comorbidities to be controlled if the BP was less than 130/80 mm Hg.
To examine factors associated with medication adherence, we employed multivariate logistic regression models controlling for patient characteristics. The dependent variable was medium-to-high medication adherence (MMAS-8 score ≥ 6) as compared to low medication adherence (MMAS-8 score < 6). We included age, gender, race/ethnicity, and selfreported health status in the model. We used the largest category in each group as the reference group.
To analyze the association between medication adherence and patient experiences with care, we examined a series of separate logistic regression models for each of the 8 patient experience measures. Each model estimated overall differences in medication adherence associated with patient experience (fixed effects model), adjusting for patient age, gender, race/ ethnicity, self-reported 5-category general health status, and clustering of patients by site. The model adjusts for clustering by patient/site using a unique patient identifier. Cluster analysis is a multivariate method which accounts for potential similarities of groups of patients by site. The dependent variable was medium-to high-medication adherence (MMAS-8 ≥ 6) vs. low adherence (MMAS-8 < 6).
Similarly, we used multivariate logistic regression models to examine the association between medication adherence and hypertension control while controlling for age, gender, race/ethnicity, self-reported health status, and clustering of patients. The dependent variable was the BP control rate (controlled vs. not controlled).
Sensitivity analyses were performed around the definition of the adherence outcome. In addition to our primary outcomes, we examined high adherence (MMAS = 8) vs. medium/low adherence (MMAS < 8). All analyses were performed in SAS 9.2 (SAS Institute, Cary, NC). This study was approved by the University of Rochester Research Subjects Review Board.
RESULTS
We collected 2,128 surveys (65.7% minimum response rate) from hypertensive patients at 3 urban safety-net practices in upstate New York (Site1 N = 642; Site2 N = 683; Site3 N = 803). Table 1 describes the characteristics of the pooled sample. The population was 59.6% female and 52.5% African American. A total of 798 respondents (37.5%) reported low adherence and 1,330 (62.5%) reported medium-to-high adherence. The overall BP control rate was 57.3%. (Table 3) . Poor health status vs. excellent or good health status was associated with lower odds of medium-to-high adherence (AOR 0.43; 95% CI 0.28-0.64). Table 4 identifies factors associated with medium-tohigh medication adherence (MMAS ≥ 6), adjusting for patient age, gender, race/ethnicity, self-reported 5-category general health status, and the clustering of patients. The concern the physician showed for patient questions (AOR 1.4; 95% CI 1.1-1.7), efforts to include the patient in decisions about treatment (AOR 1.5; 95% CI 1.2-1.9), information the provider gave about medications (AOR 1.3; 95% CI 1.0-1.6), the overall rating of care received during the visit (AOR 1.4; 95% CI 1.1-1.8) were all associated with higher medication adherence. Patients response to recommending the clinical provider (AOR 1.3; 95% CI 1.1-1.6) and clinical site (AOR 1.35; 95% CI 1.1-1.7) were also associated with higher medication adherence. The amount of time the provider spent was not statistically associated with medication adherence (AOR 1.2; 95% CI 0.9-1.4). We observed a dose-response between the mean MMAS score and the BP control rate. Among the low-adherence group, the mean MMAS score was 4.3 and the BP control rate was 51.6%. Among the medium adherence group, the mean MMAS score was 6.8 and the BP control rate of 56.3%. Among the high adherence group, the mean MMAS score was 8 and the BP control rate was 75.6%. In models adjusted for patient age, gender, race/ethnicity, general health status, and clustering of patients, medium-to-high medication adherence was associated with increased hypertension control (AOR 1.3; 95% CI 1.0-1.8) ( Table 5) .
In sensitivity analyses, similar findings were observed with modeling factors associated with high medication adherence (MMAS = 8) compared to medium-to-low adherence (MMAS < 8), except the association between recommending the clinic site and medication adherence lost statistical significance. (See Supplementary Appendix Table S2 [available online] for results of sensitivity analyses).
DISCUSSION
Improving medication adherence is a fundamental aspect to effective chronic disease management. Our study found that several elements of the patient experience with care were independently associated with higher medication adherence. These findings underscore the importance of communication and the patient-provider relationship toward improving medication adherence.
Several factors were associated with higher medication adherence scores: (i) the concern that the provider demonstrated for patients' questions or worries, (ii) the patient's overall rating of care, and (iii) their recommendation of the provider and clinic site. This highlights the importance of communication and the development of the patient-provider therapeutic relationship. Empathy effectively expressed by providers is a powerful tool that has the ability to convey the importance of adherence, and in turn improve hypertension control rates. Prior literature has similarly demonstrated that collaborative communication correlated with better medication and appointment adherence. 23, 24 Focus groups have further identified that a trusting patient-provider relationship may enhance medication adherence. 22 Combined, these results demonstrate how elements of the patient experience can influence medication adherence and support patients' self-management of hypertension. In addition, we found that the information the provider gave about medications was also associated with higher adherence. Efforts to improve patients' understanding of medication benefits, enhancing patient knowledge regarding the underlying disease, and addressing any concerns about potential side effects are important steps toward improving adherence. 28 In contrast, we found that the amount of time the provider spent with the patient was not statistically associated with reported medication adherence. This suggests that the quality of communication (e.g., showing concern and providing information) and the overall experience was more important that the absolute quantity of time. Prior literature has not directly examined the association between medication adherence and length of visit, but adherence to follow-up appointments in other settings has not been associated with length of visit time. 29, 30 The need to spend adequate time with patients should not be minimized, but these findings emphasize the importance of recognizing the overall patient experience as well.
Consistent with prior literature, we found that a sizeable proportion of patients reported sometimes forgetting to take their high BP medications. 7 Phone and text reminders may provide some benefit, 15,17 but a recent large trial found that other low-cost reminder devices were not effective at improving medication adherence. 21 The authors concluded that the devices may be more effective if coupled with patient-provider interventions to ensure consistent use. Our findings further highlight the importance of patientprovider interactions to influence the multidimensions of medication adherence. Providers can play a critical role in improving medication adherence through such actions as (i) imparting knowledge about medications, (ii) modifying patients' beliefs and fears about medications, and (iii) improving communication and trust, all areas advocated to improve medication adherence by the Centers for Disease Control and Prevention's Million Hearts campaign.
Improved patient experience with care has been associated with better clinical outcomes, patient safety, and less health care utilization. 31 As our national health care system advances toward great accountability for quality, it will become increasingly important to develop strategies to improve the patient experience with care and adherence to treatments and medications. Multiple national quality metrics incorporate medication adherence and patient experience measures to define quality of care, further highlighting the importance of the patient-provider relationship.
Our study had several limitations. The study used a convenience sample of patients from 3 separate clinics with similar underserved populations. The convenience sample introduces the possibility of sampling bias and may not accurately represent the entire hypertensive population at each site. This limits inferences and conclusions about causality. To account for sampling at discrete sites, we adjusted for clustering in our analysis. Although we used a validated instrument, self-reported medication adherence may be over-reported by patients. There is little reason, however, to believe that there would be differential rates of over-reporting of adherence. Although we adjusted for multiple patient-level factors, we were not able to account for mental health, socioeconomic variables, lifestyle measures, patients' perceptions about disease, medication side effects, chronicity of hypertension, or the duration of the patient-provider relationship.
In conclusion, we found that many elements of the patient's experience with care and patient-provider interaction are associated with higher medication adherence. Inclusive decision making and the concern the provider demonstrated for questions and patient concerns were both independently associated with higher adherence. The amount of time the care provider spent with the patient, however, was not statistically associated with higher medication adherence, suggesting that the quality of communication and overall experience may be more important than the absolute quantity of time. Our findings emphasize the importance of the patient-provider relationship, reducing worries and fears, imparting knowledge about medications, and building trust as a means toward improving adherence to treatment. 
